Clinical Guidelines Library

Clinical Practice Guidelines (10)

	Title	Condition	Source	Evidence Level	Category	Last Updated
	JNC 8 Hypertension Management Guidelines	Hypertension	JNC8	A	Cardiology	2023
Key Recommendations Initiate drug treatment at BP ≥150/90 for patients ≥60 years Goal BP <150/90 for patients ≥60; <140/90 for patients 18–59 Thiazide diuretics, ACE inhibitors, ARBs, or CCBs as first-line agents Non-Hispanic Black population: thiazide or CCB first-line Monitoring Parameters BP check at every visit; home monitoring recommended Electrolytes and Cr at baseline, 1 month, then 6 months for ACE/ARB/diuretics EKG if cardiac symptoms develop Full Guideline
	ADA Standards of Medical Care in Diabetes	Type 2 Diabetes	ADA	A	Endocrinology	2025
Key Recommendations HbA1c goal <7% for most non-pregnant adults Metformin remains first-line pharmacologic agent SGLT-2 inhibitors or GLP-1 agonists for patients with CVD, CKD, or CHF Annual lipid panel, urine albumin, and eye exam Medication Guidance Consider GLP-1 RA for weight management and CV risk reduction SGLT-2 inhibitor in CKD for renoprotection Review all diabetes medications at each visit for hypoglycemia risk Full Guideline
	GOLD COPD Strategy Report	COPD	GOLD	A	Pulmonology	2024
Key Recommendations Spirometry for diagnosis (FEV1/FVC <0.7 post-bronchodilator) LAMA or LABA as first-line for Group B/E patients Annual influenza vaccine; one-time pneumococcal vaccine Pulmonary rehab for FEV1 <50% or frequent exacerbations Monitoring Parameters Annual spirometry in patients with symptoms or exacerbations Pulse oximetry at each visit; 6MWT annually CAT or mMRC score for symptom burden tracking Full Guideline
	ACC/AHA Heart Failure Management Guidelines	Heart Failure	ACC/AHA	A	Cardiology	2022
Key Recommendations — HFrEF GDMT: ACE-I/ARB/ARNI + beta-blocker + MRA + SGLT-2 inhibitor Entresto (sacubitril/valsartan) preferred over ACE-I in ambulatory HFrEF ICD for EF ≤35% on GDMT ≥3 months with NYHA II–III Monitoring Parameters Daily weight monitoring; alert if >3 lb/day or 5 lb/week BNP or NT-proBNP at each decompensation Echo every 3–6 months during GDMT titration Full Guideline
	USPSTF Preventive Services Recommendations	Preventive Care	USPSTF	B	Preventive	2024
A/B Grade Recommendations Colorectal cancer screening: adults 45–75 Breast cancer screening: biennial mammography ages 40–74 Hypertension screening: all adults ≥18 Depression screening: all adults including pregnancy Lung cancer screening: LDCT for 50–80 yo with 20 pack-year history Quality Measure Alignment These USPSTF A/B recommendations align directly with HEDIS measures tracked in the quality program. Completion rates are reported in provider profiling and affect incentive program performance scores. Full Guideline
	KDIGO CKD Management Guidelines	CKD	KDIGO	A	Nephrology	2024
Key Recommendations BP goal <120 mmHg systolic for adults with CKD RAAS blockade (ACE-I or ARB) for CKD with albuminuria SGLT-2 inhibitor for CKD with T2DM regardless of HbA1c Nephrology referral for eGFR <30 or rapidly declining GFR Monitoring Parameters eGFR and urine ACR every 3–6 months (stage 3+) Serum K+ 1–2 weeks after ACE-I/ARB initiation or dose change Hemoglobin every 3 months if eGFR <30 Full Guideline
	ACC/AHA Cholesterol Management Guidelines	Dyslipidemia	ACC/AHA	A	Cardiology	2023
Key Recommendations High-intensity statin for ASCVD patients or LDL ≥190 Moderate statin for T2DM patients 40–75 years Fasting lipid panel at baseline and 4–12 weeks after initiation Consider ezetimibe or PCSK9 inhibitor if LDL remains ≥70 on max statin Monitoring Baseline CK and LFTs; repeat if symptoms develop Annual lipid panel when at goal; every 3–6 months during titration Full Guideline
	AACE/ACE Obesity Management Guidelines	Obesity	AACE	B	Endocrinology	2023
Key Recommendations Lifestyle intervention first-line for BMI ≥25 Pharmacotherapy for BMI ≥30 or ≥27 with comorbidities GLP-1 RA (semaglutide, liraglutide) as preferred pharmacotherapy Bariatric surgery referral for BMI ≥40 or ≥35 with comorbidities Monitoring Parameters Weight, BMI, waist circumference at each visit Review medication efficacy at 12 weeks (≥5% weight loss expected)
	APA Practice Guidelines for Depression	Depression / MDD	APA	A	Behavioral Health	2023
Key Recommendations Antidepressants and/or psychotherapy for moderate–severe MDD PHQ-9 for diagnosis and monitoring; response defined as ≥50% reduction Continue antidepressant ≥6 months after remission; longer for recurrent MDD Monitoring PHQ-9 every 2–4 weeks for first 8 weeks of treatment Assess suicidality at every visit; safety plan if risk identified
	IDSA Pneumonia Community-Acquired Treatment Guidelines	Pneumonia (CAP)	IDSA	A	Infectious Disease	2022
Key Recommendations CURB-65 score for severity assessment (hospitalize if ≥2) Outpatient CAP: amoxicillin or doxycycline for healthy adults Inpatient CAP: beta-lactam + macrolide, or respiratory fluoroquinolone Duration: 5 days if clinically stable; reassess at 72h Monitoring Parameters CBC, BMP, chest X-ray at baseline Follow-up chest X-ray 6–8 weeks post-treatment for smokers ≥50 Procalcitonin for antibiotic stewardship guidance

No results found